Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases

Part of paid clinical trials in Tampa, Florida.

Sponsor
NeuroEM Therapeutics, Inc.
Study ID
NCT07049341
Status
Enrolling By Invitation

Conditions

  • Alzheimer's Disease
  • Cortico Basal Degeneration
  • Fronto-temporal Dementia
  • Neurological Diseases or Conditions
  • Parkinson Disease (PD)
  • Posterior Cortical Atrophy (PCA)

Eligibility Criteria

Sex
ALL
Age
45 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • MemorEM — DEVICE
    The MemorEM device delivers 915MHz electromagnetic waves to the head via 8 emitters in a cap worn on the head and powered by a control box and battery worn on the arm.

Study Details

Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization. Secondary Objectives: The secondary objective is to note areas of potential improvement in the progression of the subject's neurological disease and identify the potential for the MemorEM to treat neurological diseases other than Alzheimer's disease. We are also interested in Alzheimer's variants like those with ApoE4 alleles (none of the participants in the 8-person pilot were Apo-E4 positive), known mutations causing early onset Alzheimer's, and Posterior Cortical Atrophy. Study Duration: The study will be open-ended with patients continuing use of the MemorEM as they wish or when NeuroEM Therapeutics recalls the device. It is expected but optional that patients will use the devices for approximately two years. Study Design: This study will focus on the "patient experience" of using the MemorEM device over an extended time period. Patients will remain under the care of their physicians and will provide brief descriptions of their device experiences and any suggestions for improvements. This study will not require any interventions other than using the MemorEM device, which was rated as Non-Significant Risk by the Western IRB for the previous pilot trial including two extensions that raised no safety concerns over the two and a half years of treatment. Study Population: The study population will consist of various patients suffering from diagnosed neurological diseases. Patients may be selected from those diagnosed with Alzheimer's disease, Frontotemporal dementia, Posterior cortical atrophy, Corticobasal dementia, Parkinson's disease, and other neurological diseases.

Key Dates

Start date
Jul 31, 2025
Status verified
Jul 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Active Comparator: Patient Experience Arm

Primary Outcome Measure

Patient and caregiver reports on device design and use [ Time Frame: Surveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
NeuroEM TherapeuticsTampaFlorida33602-

Find similar trials in Tampa, FL

By research site
NeuroEM Therapeutics· Tampa, FL

Related Studies